BridgeBio Pharma, Inc.
For the period ended Sep 30, 2025. Filed Oct 29, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Oct 29, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 1. Financial Statements (Unaudited)
Condensed Consolidated Balance Sheets
| September 30,2025 · December 31,2024 | |||
|---|---|---|---|
| (Unaudited) | (1) | ||
| Assets | |||
| Current assets: | |||
| Cash and cash equivalents | $642,951 | $681,101 | |
| Marketable securities | 2,991 | — | |
| Accounts receivable, net | 116,518 | 4,722 | |
| Inventories | 24,527 | — | |
| Prepaid expenses and other current assets | 52,395 | 34,869 | |
| Total current assets | 839,382 | 720,692 | |
| Investment in nonconsolidated entities | 92,168 | 143,747 | |
| Property and equipment, net | 5,830 | 7,011 | |
| Operating lease right-of-use assets | 6,553 | 5,767 | |
| Intangible assets, net | 28,795 | 23,926 | |
| Other assets | 25,522 | 18,195 | |
| Total assets | $998,250 | $919,338 | |
| Liabilities, Redeemable Convertible Noncontrolling Interests and Stockholders’ Deficit | |||
| Current liabilities: | |||
| Accounts payable | $18,702 | $9,618 | |
| Accrued compensation and benefits | 56,155 | 58,329 | |
| Accrued research and development liabilities | 34,619 | 34,272 | |
| Operating lease liabilities, current portion | 5,294 | 4,506 | |
| Deferred revenue, current portion | 9,087 | 14,604 | |
| Other current liabilities (2) | 92,743 | 33,071 | |
| Total current liabilities | 216,600 | 154,400 | |
| 2031 Notes, net | 564,087 | — | |
| 2029 Notes, net | 740,380 | 738,872 | |
| 2027 Notes, net | 546,549 | 545,173 | |
| Term loan, net | — | 437,337 | |
| Deferred royalty obligations, net (3) | 836,126 | 479,091 | |
| Operating lease liabilities, net of current portion | 3,427 | 4,696 | |
| Deferred revenue, net of current portion | 13,131 | 17,095 | |
| Other long-term liabilities | 679 | 286 | |
| Total liabilities | 2,920,979 | 2,376,950 | |
| Commitments and contingencies (Note 8) | |||
| Redeemable convertible noncontrolling interests | 23 | 142 | |
| Stockholders’ deficit: | |||
| Undesignated preferred stock, $0.001 par value; 25,000,000 shares authorized; no shares issued and outstanding | — | — | |
| Common stock, $0.001 par value; 500,000,000 shares authorized; 200,230,458 shares issued and 192,633,286 shares outstanding as of September 30, 2025, 196,236,234 shares issued and 190,044,473 shares outstanding as of December 31, 2024 | 200 | 196 | |
| Treasury stock, at cost; 7,597,172 shares as of September 30, 2025; 6,191,761 shares as of December 31, 2024 | (323,276) | (275,000) | |
| Additional paid-in capital | 2,018,335 | 1,903,155 | |
| Accumulated other comprehensive income | 2 | 8 | |
| Accumulated deficit | (3,628,331) | (3,096,263) | |
| Total BridgeBio stockholders’ deficit | (1,933,070) | (1,467,904) | |
| Noncontrolling interests | 10,318 | 10,150 | |
| Total stockholders’ deficit | (1,922,752) | (1,457,754) | |
| Total liabilities, redeemable convertible noncontrolling interests and stockholders’ deficit | $998,250 | $919,338 | |
(1)The condensed consolidated balance sheet as of December 31, 2024 is derived from the audited consolidated financial statements as of that date.
(2)Including a related party amount of $1,647 as of September 30, 2025 (as described in Note 10).
(3)Including a related party amount of $201,242 as of September 30, 2025 (as described in Note 10).
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.